Health & Biotech
ScoPo’s Powerplays: ASX health stocks show signs of jittery recovery
Health & Biotech
Wellnex delivers full year revenue lift despite global supply chain glut, says FY23 revenue will now jump by 50%
Health & Biotech
Neurotech tackles the anguish of autism with low-THC cannabis treatment
Health & Biotech
Weed Week: Cannabis lounges in Las Vegas and Cann’s Mildura cannabis facility gets GMP licence
Health & Biotech
Medlab Clinical heads for Nasdaq listing and land of opportunity
Health & Biotech
Osteopore hard at work on the next generation of its 3D-printed bioresorbable implants with focus on the large orthopaedic market
Health & Biotech
ASX Health Stocks: Cann’s Mildura cannabis facility gets GMP licence, unlocking export markets
Health & Biotech
Opyl joins forces with two key patient advocate groups
Health & Biotech
ASX Health Stocks: UK grants Invex approval to start Phase 3 trial, share price surges 11pc
Health & Biotech
ASX Health Stocks: Orthocell up 35pc after shaking on exclusive global patent deal
Health & Biotech
CardieX ratchets up commercialisation strategy with FDA lodgement for CONNEQT Pulse
Health & Biotech
Study finds Medlab on right track to advance drug delivery for better patient outcomes
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.